recap revenu miss blame transient
headwind w/ manag confid end market
report soft result revenu estim despit
fx tailwind organ revenu growth also well
expect jpme attribut mass spec under-perform
due sluggish start biomed research salesforc disrupt
recent territori realign part growth initi well transient
soft india sale result fiscal year-end pullback
relat gst end market pharma saw sequenti slowdown cc
vs cc comp industri remain soft cc due difficult comp
moder china region america remain stabl cc us
cc europ cc due industri academia weak asia
flat cc due aforement india pullback china hsd
posit note compani author addit share buy-back
provid cushion bottom line
term guidanc compani maintain fy guidanc msd cc growth
fx expect tailwind rais ep rang
previous overal clearli
disappoint stock much top-lin miss attribut
transient headwind manag remain confid end market trend
improv commerci execut throughout year said
stock still trade price-to-earnings even declin morn
continu see better opportun name greater opm potenti and/or
 option a/dhr/tmo better top line growth
maintain neutral dec pt
revenu miss expect weak pharma cc
industri cc report revenu came consensu
jpme despit fx tailwind organ growth
also well expect jpme end market pharma
saw sequenti slowdown cc vs cc comp industri
remain soft cc due tough comp moder china
region america remain stabl cc us cc europ cc
due industri academia weak asia flat cc due india
order pullback china hsd bottom line ep came
jpme/street despit top-lin miss in-lin opm
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
guidanc framework updat along addit share buy-back
author along quarterli result manag updat
guidanc framework continu call msd cc revenu growth
fx tailwind top expect improv ms commerci execut
pickup india along fundament healthi end market move
 manag maintain expect gross margin
modest opex leverag tax rate rais ep rang
previous compani expect cc
growth fx tailwind ep vs consensu
addit compani author addit share buy-back
spread next three year factor current ep guidanc
provid addit cushion year
maintain neutral step back clearli disappoint quarter
stock open much top-lin miss attribut
transient headwind manag remain confid end market trend
improv commerci execut rest year
said stock still trade price-to-earnings even declin hit
morn continu see better opportun name greater opm
expans potenti and/or option a/dhr/tmo better top line
growth maintain neutral decemb pt
invest thesi valuat risk
given near-peak margin structur unlik improv meaning
current level view increas competit dynam believ
name within coverag univers present appeal risk-reward could
look becom construct pullback compani still gener
signific cash flow highest oper margin within industri
continu endors high-roic invest
price target deriv dcf analysi use termin growth
wacc
risk rate price
downsid risk price target neutral rate includ declin within
pharmaceut industri market europ greater-than-
expect cannib base mass spectrometri busi new product
share loss competitor agil thermo/dionex
greater-than-anticip impact competit introduct uplc
upsid risk price target neutral rate includ greater-than-
anticip traction newer product well outsiz growth
lc ms servic
good sold
chang gross margin y/i bp
chang op margin y/i bp
pv termin valu
perpetu growth rate
enterpris valu
water summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
compani discuss report price report market close april
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect person view subject secur issuer part
research analyst compens directli indirectli relat specif recommend view
express research analyst report korea-bas research analyst list front cover also certifi per
kofia requir analysi made good faith view reflect opinion without undu influenc
